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رد: سرطان خلية بالزما الدم األويل
تقرير حالة ومراجعة األدبيات
Re: Primary Plasma Cell Leukaemia
Case report and review of the literature
Dear Editor, 
I read with interest the recent case report by Singh et al. published in the August 2018 issue of SQUMJ, in which the 
authors describe a 69-year-old male patient with rectal bleeding associated with pallor, dyspnoea and chest pain.1 
Laboratory tests showed microcytic hypochromic anaemia, leukocytosis, low platelets and a high erythrocyte sedim- 
entation rate. Elevated levels of urea, creatinine, uric acid, immunoglobulin D, kappa light chains and β2-micro-
globulins were also detected, while abdominal, thoracic and skeletal imaging did not show any abnormalities.1 A 
bone marrow aspirate revealed 61% atypical plasma cells. Subsequently, a diagnosis of primary plasma cell leukaemia 
(PCL) was confirmed and bortezomib-based chemotherapy was administered, resulting in a good response.1
Myeloma cells can travel to the peripheral blood if expression of the cell adhesion molecule cluster of differ-
entiation (CD)56 decreases.2,3 Along with CD19, CD20 and CD23 positivity, this phenomenon is often observed 
among patients with primary PCL, while the positive expression of CD28 and interleukin-6 are considered imp-
ortant in secondary cases.2,3 Leukocytosis, high levels of lactate dehydrogenase and β2-microglobulins and the 
presence of bone lesions can help to differentiate primary PCL from myeloma.4 Singh et al. therefore highlighted the 
need for consensus guidelines in primary healthcare for the purposes of early diagnosis and prompt and adequate 
treatment.1 Other case reports have also emphasised the diagnostic pitfalls associated with unsuspected cases of 
myeloma, rib plasmacytoma, multiple myeloma and secondary PCL.4–6 These cases may help to enhance suspicion 
of plasma cell malignant disorders among primary healthcare workers.
Dos Santos et al. reported a 53-year-old female patient with multiple myeloma and secondary PCL; the patient had 
25% plasma cells in a bone marrow aspirate and positive expressions of lambda light chains, CD56 and CD20 as 
well as 23% circulating peripheral blood plasma cells.4 She had high levels of urea and creatinine and was hyperc-
alcaemic and anaemic. An X-ray showed radiolucent speckled areas in the humeral diaphysis with no evidence of 
organomegaly or lymphadenopathy.4 A diagnosis of leukaemia was made, based on the presence of >2,000/mm3 
circulating plasma cells, some of which were dysplastic. Subsequently, the patient demonstrated significant clinical 
improvement following treatment with dexamethasone, cyclophosphamide, thalidomide, cisplatin, doxorubicin 
and etoposide.4
Another case report described a 65-year-old female patient who was diagnosed with rib plasmacytoma, overt 
immunoglobulin (Ig)-A-producing multiple myeloma and hyperviscosity syndrome.5 She had a history of dyspnoea 
and a mental disorder and subsequently developed chronic renal failure, respiratory disturbance and 
heart failure. Bio-chemistry tests showed elevated urea, creatinine and calcium levels and β2-microglobulins; in 
addition, she was anaemic and her IgA and kappa light chain levels were 8,917 mg/dL (normal range: 153–359 mg/dL) 
and 2,990 mg/dL (normal range: 625–1,668 mg/dL), respectively.5 The presence of >50% plasma cells with basophilic 
cytoplasm, eccentric nuclei and large nucleoli in a bone marrow biopsy established the diagnosis of multiple myeloma. 
The patient was treated with dexamethasone and underwent plasmapheresis without improvement.5
Finally, dos Santos et al. reported a 64-year-old male patient who presented with dizziness, fatigue, dyspnoea, 
lumbar pain and high levels of calcium, urea and creatinine.6 Multiple osteolytic lesions were detected in the cranium and 
lumbar spine, in addition to a monoclonal peak in the gamma region and high levels of IgG. A bone marrow aspirate 
revealed >40% plasma cells.6 The patient was eventually diagnosed with multiple myeloma at a late stage, due partly 
to a history of activities resulting in overload on the axial skeleton because of his profession as a construction 
foreman, as well as nonsteroidal anti-inflammatory drug abuse. He underwent chemotherapy which resulted in an 
unsatisfactory response.6
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Response from the Authors
Dear Reader,
Thank you for your letter highlighting similar cases of unsuspected multiple myeloma and primary or secondary 
plasma cell leukaemia (PCL).1–3 There are certain points upon which we wish to elaborate. Firstly, as mentioned 
in the original publication by Singh et al., a decrease in the expression of cluster of differentiation (CD)56 is a 
reliable marker of PCL.4 However, in the 40–50% of cases wherein CD56 is not expressed, diagnostic difficulties 
ensue.5 Secondly, flow cytometry has proven to be a valuable adjunct in diagnosing myeloma and/or PCL.6 This 
method should therefore be paired with bone marrow and peripheral blood flow cytometry for the detection of 
circulating plasma cells by using CD markers such as CD27, CD28, CD117, CD200, CD229 and CD81. Specifically, 
the expression of MYC, cyclin D1 and p53 in bone marrow biopsies can differentiate between different types of 
PCL, as cyclin D1 is exclusive to primary PCL, while the other two markers are seen in both forms.7 Thirdly, we wish 
to caution against the interchangeable usage of the terms dysplastic and anaplastic.2
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